2'-FL supplement study for Crohn’s or ulcerative colitis remission
Part of Digestive system clinical trials.
This trial tests whether a dietary supplement called 2'-FL is safe and practical for teens and young adults with Crohn’s or ulcerative colitis who are in remission. It also looks at how well the supplement fits into daily life while you stay on a stable anti-TNF medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 11 to 25, and you have Crohn’s disease or ulcerative colitis
- Your gut symptoms must be in remission based on clinic scoring (not actively flaring)
- You must not take corticosteroid medicines (like prednisone) right now
- You must be on a stable anti-TNF maintenance dose (adalimumab, infliximab, or infliximab-dyyb) for at least 12 weeks
- You can’t plan major diet changes during the study (like switching to vegan, SCD, or exclusive tube feeding nutrition)
- You need to avoid certain meds like antibiotics/probiotics/prebiotics during the prior month and avoid other investigational treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study tests whether a special fibre supplement can reduce inflammation in people with active ulcerative colitis. You take the supplement daily for a few weeks, and researchers check how it affects your symptoms and gut health.
This study tests whether combining a specific diet with biologic medicines can reduce active inflammation and symptoms of Crohn’s disease. It may help people who still have active disease in the bowel despite prior care.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This trial compares a steroid called prednisolone to a special diet (aCDED with PEN) for treating Crohn's disease flare-ups. It aims to see which approach helps improve quality of life.
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.